Table 1 Characteristics of patients in the per-protocol population
Nitrous oxide/oxygen plus acetaminophen (n = 315) | Morphine (n = 329) | |
|---|---|---|
Age, years, mean ± SD | 61.9 ± 13.7 | 62.1 ± 13.0 |
Male sex, n (%) | 255 (81.0) | 249 (75.7) |
Body mass index,a kg/m2 | n = 296 | n = 307 |
Median (Q1; Q3) | 25.8 (23.7; 28.1) | 26.0 (23.9; 29.0) |
≥30 kg/m2, n (%) | 42 (14.2) | 58 (18.9) |
Smokers, n/N (%) | 147/314 (46.8) | 150/321 (46.7) |
Diabetes,bn/N (%) | 36/312 (11.5) | 38/323 (11.8) |
Hypertension, bn/N (%) | 131/312 (42.0) | 119/318 (37.4) |
Hypercholesterolaemia, bn/N (%) | 82/305 (26.9) | 95/315 (30.2) |
Family history of cardiovascular disease, n/N (%) | 94/274 (34.3) | 87/278 (31.3) |
Previous coronary artery disease, n/N (%) | 55/311 (17.7) | 56/324 (17.3) |
Thrombolysis, n (%) | 30 (9.5) | 46 (14.0) |
Decision of angioplasty, n (%) | 296 (94.0) | 308 (93.6) |
Treatments at baseline, n (%) | ||
Aspirin | 313 (99.4) | 323 (98.2) |
Other antiplatelet (clopidogrel, ticagrelor or prasugrel) | 301 (95.6) | 314 (95.4) |
Clopidogrel | 54 (17.1) | 56 (17.0) |
Ticagrelor | 168 (53.3) | 145 (44.1) |
Prasugrel | 81 (25.7) | 116 (35.3) |
Heparin | 136 (43.2) | 163 (49.5) |
Low-molecular-weight heparin | 159 (50.5) | 124 (37.7) |
Bivalirudin | 21 (6.7) | 32 (9.7) |
Anticoagulant (heparin, low-molecular-weight heparin or bivalirudin) | 307 (97.5) | 318 (96.7) |
Beta-blocker | 4 (1.3) | 0 |
Glycoprotein IIb/IIIa inhibitor | 6 (1.9) | 9 (2.7) |
Anxiolytic | 2 (0.6) | 10 (3.0) |
Other treatment (administered in mobile intensive care unit) | 47 (14.9) | 69 (21.0) |
Delay between chest pain and study treatment start, minutes | n = 314 | n = 329 |
Median (Q1; Q3) | 91.0 (65.0; 161.0) | 100.0 (62.0; 167.0) |
Pain score on numeric rating scale at study treatment start | n = 314 | n = 328 |
Median (Q1; Q3) | 7.0 (5.0; 8.0) | 7.0 (5.0; 8.0) |